1/1
2 files

Supplementary Figures – First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

figure
posted on 11.11.2021, 10:00 authored by Shigemasa Takamizawa, Yusuke Okuma, Yasuhiro Kato, Taiki Hakozaki, Shingo Kitagawa, Yoshitaka Zenke

Supplementary Figure 1. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

CONSORT diagram of patient selection. EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PS, performance status

Supplementary Figure 2. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

The changes in ECOG-PS score due to treatment with osimertinib. The blue, black, and red line indicates the patients whose baseline of PS was 4, 3, and 2, respectively. ECOG-PS, Eastern Cooperative Oncology Group-performance status

History